

(3) Present vision of wholesale drug industry and functions required

+ Comprehensive Action Plan including development of generic and non-prescription drug market, promotion of more efficient and advanced distribution

'Public-Private Dialogue for

Innovative Drug Discovery'

View of Changes in 5 Years Following Formulation of Drug Industry Vision and Formulation of New Vision

Changes in 5 years following formulation of previous Vision (2002), basic direction of Japan (promotion of innovation and faster growth)

O Greater M & A activity, global expansion, increase in number of clinical trial notifications etc.

No increase in share of Japan-origin global blockbuster drugs, no blockbusters produced in Japan since 2000 etc.

Japanese companies lack global competitiveness

O Drug lag problem, lagging behind in multinational clinical trials

--- Decline in global competitiveness of Japan's drug market

O Acceleration of economic growth rate and promotion of innovation – the political challenges faced by overall government

- Drug industry in particular is the 'prime' field for generating innovation to contribute to economic growth

Formulation of New Drug Industry Vision

Objective: To boost the global competitiveness of Japan's drug industry and eliminate the drug lag Ultimately aspire to become a country with the affluence to 'deliver as quickly as possible and at reasonable prices safe and high-quality drugs in line with healthcare needs'

Requirements for Boosting Global Competitiveness and Eliminating the Drug Lag



Vital to make Japan's drug discovery environment and market open and globally consistent

Direction of New Vision Measures

A comprehensive Industry Vision based on the '5-Year Strategy for the Creation of Innovative Drugs and Medical Devices' with the addition of the vision of the industry, the image of related industry expansion and the measures required

Requirements of the Drug Industry

Drugs are life-related products, with high value and heavy burden of social responsibility → Boosting global competitiveness is not the only requirement of pharmaceutical companies

Requirements of the drug industry

- To respond to unmet medical needs
- To develop and supply unprofitable but vital drugs (agents for refractory diseases with no available therapeutic methods, orphan drugs, vaccines etc.) and drugs to meet the needs in Japan and Asia
- To make social and international contributions through humanitarian assistance to developing countries, crisis management of new influenza strains, natural disasters, bioterrorism etc.

<u>* The establishment in Japan of research bases and the development of new</u> <u>drugs originating in Japan</u> by pharmaceutical companies should be welcomed. The grant of government aid to such companies should also be fully considered.

Vision of Pharmaceutical Industry

On the basis of drug cost increases in line with national healthcare expenditure, in 2015 and 2025 the future drug market could respectively be 1.3 times and 1.7 times that of 2005.

The global market is increasing at a huge rate \longrightarrow the emergence of a major market is expected

- Ongoing new drug development, innovation, efforts at global expansion are required for the drug industry to keep up with this rate of increase
- Given industry progress in line with the '5-Year Strategy for the Creation of Innovative Drugs and Medical Devices', Japan too could easily become a new drug development base alongside **Europe and the US**

Ongoing new drug development, innovation, global expansion require a certain corporate scale




There are limits to the conventional global megapharma model (repeat mergers, concentration on development of major products)


New stage of global competition (Maturity of existing products, more targeted drug development)

Expansion to the right size, search for fields with global-leader potential, increase in competitive product line-up

Potential to compete against major global firms in new drug development

Japan production of at least $1/4 \sim 1/3$ of new active ingredients also not impossible





Vision of Drug Retailing

Realities	 No. of drug retailers: approx. 86,000 (approx. 51,000 pharmacies, 11,000 drug-sellers with first-class, 13,000 with second-class and 10,000 with third-class license (03/2005) Increase in no. of pharmacies through advance of bungyo; decrease in no. of drug-sellers with first-class, second-class and third-class license Establishment of risk-proportionate marketing system for non-prescription drugs (PAL revision of 2006) → High-risk drugs containing ingredients requiring particular safety precautions only sold by pharmacies → Non-prescription and other relatively low-risk drugs sold by pharmacies and registered sellers
	O Tougher intro industry competition for drug retailors through diversification of energies and
	O Tougher intra-industry competition for drug retailers through diversification of operators and
	tougher cross-industry competition through deregulation
	\rightarrow Establish role as local health stations
	O Rapid advance of IT
Challenges	\rightarrow Apply IT in distribution for purchasing and inventory management etc.
8	O Crucial role as local base for the supply of drugs etc. following advance of bungyo and
	healthcare reforms
and	\rightarrow Respond to local healthcare policies
anu	(Act as primary care pharmacy, implement high-quality bungyo, improve local healthcare etc.)
	O Role of primary care pharmacy
Vision	\rightarrow • Take an active part in minor healthcare services through promoting the use of switch OTC
VISION	and other non-prescription drugs
	 Support home healthcare Support promotion of congrise
	Support promotion of generics

Basic Concept of Drug Industry Policies

